Linear IgA Bullous Dermatosis (LABD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Linear IgA bullous dermatosis (LABD) is a rare acquired autoimmune subepithelial bullous disease characterized by linear deposition of IgA along the basement membrane zone (BMZ) targeting several autoantigens. The clinical presentation is heterogeneous and can mimic other blistering disorders such as dermatitis herpetiformis and bullous pemphigoid. However, characteristic cutaneous lesions consist of tense arciform bullae in a ‘string-of-pearls’ configuration. LABD can affect adults and children with similar histological and immunopathological features. LABD generally shows spontaneous resolution in children but not adults. Most cases of childhood LABD are idiopathic, but drugs and infections were reported as potential triggering factors. In adults, malignancies and influenza vaccination also may act as triggers. The child appeared restless and distressed by an intense itch. Lesional and perilesional biopsies were taken from the buttocks for histology and direct immunofluorescence (DIF).
·
The estimated incidence of Linear IgA bullous
dermatosis (LABD) ranges from 0.25 to 2.5 per million population in the USA.
Thelansis’s “Linear IgA Bullous
Dermatosis (LABD) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2022 To 2032" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Linear IgA
Bullous Dermatosis (LABD) treatment modalities options for eight major markets
(USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Linear IgA Bullous Dermatosis (LABD) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Linear IgA Bullous Dermatosis (LABD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
_page-0001.jpg)
Comments
Post a Comment